David Apelian

David Apelian

Vorstandsvorsitzender bei
Theolytics Ltd.
61 Jahre
Health Technology
Consumer Services

Profil

David Apelian is currently Chief Executive Officer at Theolytics Ltd. since 2024.
Formerly, Chief Executive Officer & Director at Eiger BioPharmaceuticals, Inc. from 2022 to 2024, Chief Executive Officer & Director at BlueSphere Bio, Inc. from 2019 to 2022, Chief Medical Officer & Executive Vice President at Achillion Pharmaceuticals, Inc. from 2013 to 2017, Chief Medical Officer, SVP-Research & Development at GlobeImmune, Inc. from 2008 to 2013, Clinical Director-Infectious Diseases Group at Bristol Myers Squibb Co. from 2002 to 2004, Clinical Director-Hepatology Department at Schering-Plough Corp.
from 1999 to 2002, and Vice President at Wyeth Pharmaceuticals LLC.
Education includes a doctorate from the University of Medicine & Dentistry of New Jersey, undergraduate and doctorate degrees from Rutgers State University of New Jersey, and an MBA from Quinnipiac University.

Aktive Positionen von David Apelian

UnternehmenPositionBeginn
Vorstandsvorsitzender 17.12.2024

Ehemalige bekannte Positionen von David Apelian

UnternehmenPositionEnde
EIGER BIOPHARMACEUTICALS Vorstandsvorsitzender 01.09.2024
Vorstandsvorsitzender 04.10.2022
ACHILLION PHARMACEUTICALS, INC. Technik-/Wissenschafts-/F&E-Leiter 28.12.2017
GLOBEIMMUNE, INC. Technik-/Wissenschafts-/F&E-Leiter 01.01.2013
BRISTOL-MYERS SQUIBB COMPANY Technik-/Wissenschafts-/F&E-Leiter -
Sehen Sie sich die Erfahrung von David Apelian im Detail an

Ausbildung von David Apelian

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

63

Beziehungen ersten Grades

11

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

  1. Börse
  2. Insiders
  3. David Apelian